Mod GRF 1-29 (CJC-1295 Without DAC): The Complete Guide

Overview

Growth hormone releasing hormone (GHRH) is a 44-amino-acid peptide produced by the hypothalamus that serves as the primary physiological stimulus for GH secretion from pituitary somatotroph cells. Researchers discovered in the 1980s that the full biological activity of GHRH resides in its first 29 amino acids, designated GRF(1-29) or sermorelin. Sermorelin was subsequently developed as the first GHRH analog approved by the FDA (Geref, approved 1997 for diagnostic use, later withdrawn from market). However, native GRF(1-29) is rapidly cleaved by DPP-IV at the position 2 alanine residue, producing an inactive fragment and limiting its plasma half-life to approximately 5–7 minutes (Jetton et al., 2005).

To overcome this limitation, researchers introduced four amino acid substitutions into the GRF(1-29) backbone. These substitutions — D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 — were specifically designed to resist DPP-IV cleavage and improve metabolic stability without altering receptor binding affinity. The resulting peptide, known as tetrasubstituted GRF(1-29) or Mod GRF 1-29, retains full agonist activity at the GHRH receptor (GHRH-R) while exhibiting a plasma half-life of approximately 30 minutes, roughly a four- to five-fold improvement over native sermorelin (Ionescu & Bhatt, 2006).

The naming of this peptide has caused significant confusion in the peptide community. The name “CJC-1295 without DAC” emerged because the same research group (ConjuChem Biotechnologies) developed both the DAC-conjugated version (true CJC-1295, which binds albumin for a 6–8 day half-life) and the non-conjugated precursor. In practice, when people refer to “CJC-1295 no DAC,” they are almost always referring to Mod GRF 1-29 — the tetrasubstituted short-acting GHRH analog. These are fundamentally different compounds with different pharmacokinetics and clinical profiles, despite the confusingly similar names.

Mod GRF 1-29 occupies a specific pharmacological niche: it amplifies the GHRH signal that initiates GH release from the pituitary. However, it works through a different receptor and signaling cascade than the growth hormone releasing peptides (GHRPs), which act through the ghrelin receptor (GHSR-1a). When Mod GRF 1-29 (GHRH pathway) is combined with a GHRP such as ipamorelin (ghrelin pathway), the resulting GH pulse is synergistically larger than either agent alone — often 2–3 times greater than the sum of individual responses. This pharmacological synergy is the primary reason Mod GRF 1-29 is rarely used as a standalone agent; it is almost always paired with a GHRP (Ghigo et al., 1997).

Quick Facts

Mod GRF 1-29 vs. CJC-1295 with DAC: Critical Distinction

The distinction between these two compounds is clinically significant. CJC-1295 with DAC produces a continuous, non-pulsatile GH elevation that persists for nearly a week. While this offers dosing convenience, it eliminates the natural pulsatile pattern of GH secretion that the body has evolved to produce. Sustained GH elevation more closely resembles exogenous GH administration and carries a higher theoretical risk of side effects associated with chronic GH excess, including insulin resistance, water retention, and elevated IGF-1 levels. Mod GRF 1-29, by contrast, creates discrete GH pulses that rise and fall within hours, preserving the trough periods that are physiologically important for GH receptor sensitivity and metabolic regulation (Teichman et al., 2006).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Understanding Mod GRF 1-29's mechanism requires understanding both the GHRH signaling axis and how it differs from — and synergizes with — the GHRP/ghrelin pathway. These two systems represent the major stimulatory inputs for GH secretion, and Mod GRF 1-29 specifically targets the GHRH arm.

GHRH Receptor Activation (Primary Mechanism)

Mod GRF 1-29 is a full agonist at the growth hormone releasing hormone receptor (GHRH-R), a G-protein-coupled receptor (GPCR) expressed on the surface of pituitary somatotroph cells. The GHRH-R couples to the stimulatory Gs protein, and its activation triggers the following signaling cascade:

1. Receptor binding: Mod GRF 1-29 binds to the GHRH-R on somatotrophs with affinity comparable to native GHRH, despite its four amino acid modifications. The substitutions were specifically chosen to affect metabolic stability without altering the receptor-binding epitope (Ionescu & Bhatt, 2006).
2. Gs protein activation: Receptor binding activates the Gs alpha subunit, which in turn stimulates adenylyl cyclase.
3. cAMP production: Adenylyl cyclase converts ATP to cyclic adenosine monophosphate (cAMP), the primary second messenger in the GHRH pathway.
4. Protein kinase A (PKA) activation: Elevated cAMP activates PKA, which phosphorylates multiple downstream targets including CREB (cAMP response element-binding protein).
5. GH gene transcription and vesicle exocytosis: PKA activation has a dual effect: it promotes GH gene transcription (increasing GH synthesis over hours) and triggers exocytosis of pre-formed GH-containing secretory vesicles (producing rapid GH release within minutes) (Mayo, 1992).

The result is a rapid pulse of GH secretion that peaks within 15–30 minutes of subcutaneous injection, with GH levels returning toward baseline over 2–3 hours as the peptide is cleared and the signaling cascade attenuates.

DPP-IV Resistance: The Four Substitutions

The critical innovation of Mod GRF 1-29 lies in its four amino acid substitutions, each serving a specific purpose in protecting the peptide from enzymatic degradation:

The net effect of these four modifications is a roughly 4–5 fold improvement in plasma half-life (from ~7 minutes to ~30 minutes) while maintaining full GHRH receptor agonist activity. This is a critical distinction from CJC-1295 with DAC, where the half-life extension comes not from amino acid modifications but from a reactive chemical group (maleimido acid) that forms a covalent bond with serum albumin after injection, creating a long-lived peptide-albumin conjugate (Ionescu & Bhatt, 2006).

Synergy with GHRPs (The GHRH + GHRP Axis)

The pharmacological rationale for combining Mod GRF 1-29 with a GHRP is one of the best-characterized examples of receptor pathway synergy in endocrinology. The two systems converge on the same cellular target (the pituitary somatotroph) but through fundamentally different signaling mechanisms:

• Mod GRF 1-29 (GHRH pathway): Activates GHRH-R → Gs → adenylyl cyclase → cAMP → PKA
• GHRPs (ghrelin pathway): Activate GHSR-1a → Gq/11 → phospholipase C (PLC) → IP3 + DAG → intracellular calcium release

Both pathways independently stimulate GH vesicle exocytosis, but through different intracellular effectors (cAMP/PKA vs. calcium/PKC). When both pathways are activated simultaneously, the intracellular signals converge and amplify each other, producing a GH output that exceeds the additive sum of either stimulus alone. In human studies, co-administration of GHRH analogs with GHRPs produced GH peaks 2–3 times higher than the sum of individual responses — a true pharmacological synergy rather than a simple additive effect (Ghigo et al., 1997).

Additionally, GHRPs exert hypothalamic effects that complement the pituitary action of Mod GRF 1-29: they suppress somatostatin release from the hypothalamus. Since somatostatin is the primary inhibitory signal opposing GH release, this suppression effectively “removes the brake” while Mod GRF 1-29 “presses the accelerator.” The combination of direct somatotroph stimulation (both agents) plus somatostatin suppression (GHRP contribution) produces the maximal achievable endogenous GH pulse (Ghigo et al., 1997).

Somatostatin Interaction

Mod GRF 1-29's GH-releasing effect is partially dependent on the prevailing somatostatin tone. During periods of high somatostatin activity (e.g., the somatostatin troughs that occur between natural GH pulses), the GH response to GHRH analogs is blunted. This is because somatostatin activates inhibitory Gi-coupled receptors on somatotrophs that oppose the Gs-mediated cAMP production stimulated by GHRH (Mayo, 1992).

This somatostatin sensitivity has practical implications for dosing timing. The GH response to Mod GRF 1-29 is maximized when somatostatin tone is low — such as during deep sleep onset, upon waking in the morning, or when combined with a GHRP that suppresses somatostatin. This is one reason why the Mod GRF + GHRP combination is more reliable than Mod GRF alone: the GHRP component reduces the variability introduced by fluctuating somatostatin levels.

Pharmacokinetics

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

Mod GRF 1-29 has no FDA-approved indication. It has not undergone formal Phase III clinical trials as a standalone compound. The closely related CJC-1295 with DAC was studied in human clinical trials (Phase I/II) by ConjuChem Biotechnologies, but those trials were halted after a participant death in 2006 that was subsequently attributed to an unrelated cardiac event rather than the drug itself. Neither the DAC nor the non-DAC version has been submitted for FDA approval (Teichman et al., 2006).

The parent compound sermorelin (native GRF 1-29, without the tetrasubstitutions) was FDA-approved as Geref for diagnostic use in assessing GH secretory capacity. Geref was later voluntarily withdrawn from the market by its manufacturer (not for safety reasons) and is now available primarily through compounding pharmacies.

Primary Clinical Applications

Mod GRF 1-29 is used in clinical peptide therapy and research for the following purposes, almost always in combination with a GHRP:

The Gold Standard Stack: Mod GRF 1-29 + Ipamorelin

The combination of Mod GRF 1-29 with ipamorelin has become the most widely prescribed peptide combination in clinical GH optimization practice. The rationale for this specific pairing includes:

• Complementary mechanisms: Mod GRF 1-29 activates the GHRH receptor (cAMP pathway) while ipamorelin activates the GHSR-1a/ghrelin receptor (calcium pathway), producing synergistic GH amplification.
• Clean side effect profile: Ipamorelin is the most selective GHRP available — it produces minimal cortisol elevation, minimal prolactin elevation, and no appetite stimulation. Combined with Mod GRF 1-29 (which also has minimal off-target effects), the stack offers GH augmentation with the lowest side effect burden of any GHRH/GHRP combination.
• Low desensitization: Ipamorelin has the lowest desensitization rate among GHRPs, and GHRH analogs do not significantly desensitize the GHRH receptor with continued use. This makes the combination suitable for sustained protocols lasting months rather than requiring the strict cycling that more potent GHRPs like hexarelin demand.
• Pulsatile physiology: Both compounds have short half-lives (Mod GRF ~30 min, ipamorelin ~2 hours), producing discrete GH pulses that clear between doses, maintaining the natural trough periods essential for GH receptor sensitivity.

What Mod GRF 1-29 Is NOT Used For

• Standalone GH therapy: Mod GRF 1-29 alone produces a modest GH pulse. Without GHRP co-administration, the GH response is variable and often underwhelming. It is not effective as a solo agent for meaningful GH augmentation.
• Direct muscle building: While it increases GH, Mod GRF 1-29 is not an anabolic steroid and does not directly build muscle mass. The GH-mediated effects on body composition are indirect and modest.
• Replacement for exogenous GH in severe deficiency: Patients with organic GH deficiency (pituitary damage, tumors, radiation) may not have sufficient somatotroph reserve to respond to GHRH stimulation. These patients require exogenous GH replacement.
• Weight loss drug: The fat-mobilizing effects of GH are real but modest. Mod GRF + GHRP is complementary to diet and exercise, not a substitute for them.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Standard Dosing Protocols

Timing and Administration

• Fasted state (critical): Mod GRF 1-29 should be administered on an empty stomach — at least 30–60 minutes before eating and 2+ hours after eating. Elevated blood glucose and free fatty acids from food blunt the GH response to GHRH by increasing somatostatin tone. Eating within the GH pulse window (30–60 min post-injection) significantly attenuates the response (Ghigo et al., 1997).
• Pre-bedtime dose (most important): The single most impactful dose timing is 20–30 minutes before sleep. This augments the natural nocturnal GH surge that occurs during deep sleep onset. The combination of endogenous GHRH release during sleep plus exogenous Mod GRF + GHRP produces the largest cumulative GH pulse of the day.
• Morning dose: Administered immediately upon waking, before breakfast. This capitalizes on the post-sleep GHRH/somatostatin balance and provides a GH pulse during the active phase of the day.
• Post-exercise dose (optional third dose): If using 3x daily, the third dose can be placed 15–20 minutes post-exercise, when the exercise-induced GH response can be amplified. Must be on an empty stomach (no post-workout shake until at least 30 minutes after injection).
• Spacing between doses: Allow at least 3 hours between doses to ensure the previous GH pulse has returned to baseline before initiating a new one. Stacking doses too closely does not produce proportionally larger GH release and may reduce overall daily GH output by interfering with the trough-to-peak rhythm.

Reconstitution and Storage

• Lyophilized powder: Mod GRF 1-29 is supplied as a white lyophilized powder, typically in vials of 2 mg or 5 mg. Reconstitute with bacteriostatic water (BAC water), not sterile water (which lacks the preservative benzyl alcohol).
• Reconstitution example (2 mg vial): Adding 2 mL BAC water yields a concentration of 1 mg/mL (1,000 mcg/mL). A standard 100 mcg dose = 0.1 mL = 10 units on a U-100 insulin syringe.
• Reconstitution example (5 mg vial): Adding 2.5 mL BAC water yields 2 mg/mL (2,000 mcg/mL). A 100 mcg dose = 0.05 mL = 5 units.
• Unreconstituted storage: Refrigerate at 2–8°C. Stable for 12+ months when kept dry and cold. Can tolerate brief room temperature exposure during shipping.
• Reconstituted storage: Refrigerate and use within 3–4 weeks. Do not freeze reconstituted solution. Discard if solution becomes cloudy, discolored, or if particulate matter is visible.
• Injection technique: Subcutaneous injection using a 29–31 gauge insulin syringe, 0.5” needle. Common sites: lower abdomen (2+ inches from navel), anterior thigh, deltoid area. Rotate injection sites to prevent lipodystrophy.
• Combining in the same syringe: Mod GRF 1-29 and ipamorelin can be drawn into the same syringe for a single injection, reducing injection burden. Draw the GHRP first, then the Mod GRF. This is common practice and does not affect peptide activity.

Protocol Duration and Cycling

Unlike hexarelin and other potent GHRPs that require strict cycling, the Mod GRF 1-29 + ipamorelin combination can generally be used for extended periods (3–6 months or longer) without significant desensitization, because:

• GHRH-R does not desensitize as readily as GHSR-1a with moderate agonist exposure.
• Ipamorelin has the lowest desensitization profile among GHRPs.
• The short half-lives of both peptides ensure receptor trough periods between doses, allowing receptor resensitization.

That said, periodic cycling (e.g., 5 days on / 2 days off, or 3 months on / 1 month off) is still commonly practiced to maintain optimal receptor sensitivity and to provide assessment periods for monitoring progress and side effects.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Research and Users Report

GH and IGF-1 Response Data

Reported Timeline of Effects

What the CJC-1295 Clinical Trials Showed

While formal clinical trial data for Mod GRF 1-29 specifically is limited, the Phase I/II trials of CJC-1295 with DAC provide relevant evidence, as both compounds activate the same receptor (the DAC version simply does so for a longer duration):

• GH elevation: Single SC doses of CJC-1295 with DAC (30–60 mcg/kg) produced 2–10 fold increases in mean GH levels sustained over 6+ days. The non-DAC version produces comparable peak amplitudes but for a shorter duration (Teichman et al., 2006).
• IGF-1 elevation: After multiple weekly doses, IGF-1 levels increased by 46–98% above baseline and were sustained throughout the treatment period. The effect was dose-dependent and maintained for at least 2 weeks after the last dose (Teichman et al., 2006).
• Tolerability: CJC-1295 was well-tolerated in clinical trials. The most common adverse events were injection site reactions (erythema, pain) and transient flushing. No serious adverse events were attributed to the compound in published trial reports.
• Body composition: While formal body composition endpoints were not primary outcomes in the Phase I/II trials, trends toward decreased fat mass and increased lean mass were observed in extended-dosing cohorts.

Factors Affecting Results

• Age: Older adults (40+) with more pronounced age-related GH decline typically experience the most noticeable benefits, as the relative improvement in GH pulsatility is greatest. Younger adults with robust endogenous GH may see smaller relative improvements.
• Body composition: Obese individuals have blunted GH responses to GHRH stimulation (due to hyperinsulinemia and elevated free fatty acids). Weight loss and metabolic improvement can enhance the response to Mod GRF + GHRP therapy.
• Diet and exercise: The body composition benefits of GH augmentation are strongly potentiated by regular exercise and appropriate nutrition. GH supports fat oxidation and protein synthesis, but these effects are most meaningful in the context of an active lifestyle.
• Sleep quality: Paradoxically, better sleep improves GH secretion, and GH augmentation improves sleep. This positive feedback loop is one reason why sleep improvements are the earliest reported benefit.
• Compliance and consistency: Results correlate with consistent daily use over weeks to months. Sporadic dosing produces sporadic results.
• GHRP choice: The specific GHRP paired with Mod GRF affects both the magnitude of GH response and the side effect profile. Ipamorelin produces the cleanest response; GHRP-2 or hexarelin produce larger peaks with more side effects.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Side Effects Reported in Clinical Use

Comparison: Mod GRF 1-29 Side Effects vs. Other GH Therapies

Theoretical Risks and Long-Term Considerations

• Insulin resistance: Pulsatile GH release (as produced by Mod GRF + GHRP) carries substantially lower insulin resistance risk than sustained GH elevation, because the trough periods between pulses allow insulin sensitivity to recover. However, monitoring fasting glucose, HbA1c, and fasting insulin is still prudent during prolonged use, especially in individuals with prediabetes or metabolic syndrome.
• IGF-1 and cancer risk (theoretical): Elevated IGF-1 is a growth factor that promotes cell proliferation. The epidemiological relationship between IGF-1 levels and cancer risk is complex. Mod GRF + GHRP typically produces IGF-1 elevations within or slightly above the normal physiological range, which is considered lower risk than the supraphysiological IGF-1 levels associated with exogenous GH abuse. Nevertheless, individuals with active malignancies should avoid GH secretagogues.
• Pituitary stimulation: Long-term exogenous stimulation of pituitary somatotrophs theoretically could affect pituitary function. No evidence of pituitary hyperplasia or dysfunction has been reported with GHRH analog use in published studies up to 6–12 months.
• Unknown long-term effects: Multi-year safety data for Mod GRF 1-29 specifically does not exist. The safety extrapolation is based on sermorelin (which has more extensive clinical history) and general GHRH analog pharmacology.

Contraindications

• Active cancer or significant cancer risk factors — GH/IGF-1 promote cell proliferation
• Pregnancy and breastfeeding — no safety data available
• Children — no pediatric data outside of research settings
• Active pituitary tumors — somatotroph stimulation could theoretically worsen adenomas
• Severe, uncontrolled diabetes — GH exacerbates insulin resistance
• Known allergy to the peptide or any excipient

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Comparisons: Mod GRF 1-29 vs. Other GHRH Analogs and GH Therapies

Mod GRF 1-29 vs. Sermorelin

Sermorelin is native GRF(1-29) — the identical first 29 amino acids of human GHRH without any modifications. It was the first GHRH analog to reach clinical use (FDA-approved as Geref for diagnostic purposes). Mod GRF 1-29 was developed specifically to overcome sermorelin's shortcomings:

In practical terms, Mod GRF 1-29 is generally considered the superior GHRH analog due to its longer half-life, greater GH release per dose, and improved chemical stability. Sermorelin remains in use primarily because of its longer clinical track record and wider availability through compounding pharmacies. Many clinicians have transitioned from sermorelin to Mod GRF 1-29 as the preferred GHRH component of GHRH/GHRP protocols.

Mod GRF 1-29 vs. CJC-1295 with DAC

This is the most commonly confused comparison in the peptide community. Despite the similar names, these are pharmacologically distinct compounds:

The clinical preference for Mod GRF 1-29 over CJC-1295 with DAC in most peptide therapy protocols reflects the philosophical alignment with pulsatile, physiological GH secretion. The body naturally secretes GH in discrete pulses (primarily during sleep and after exercise), with trough periods between pulses that serve important regulatory functions. CJC-1295 with DAC eliminates these troughs, creating a pharmacokinetic profile that more closely resembles exogenous GH injection than endogenous GH physiology. Most clinicians in the peptide therapy space view pulsatile stimulation as inherently safer and more physiological for long-term use.

Mod GRF 1-29 + GHRP vs. Exogenous Growth Hormone (Somatropin)

Mod GRF 1-29 vs. GHRH (Full-Length, 1-44)

Full-length GHRH (1-44) is the endogenous 44-amino-acid hypothalamic hormone. It is occasionally available through specialty suppliers but is rarely used in clinical practice because: (1) the full 44-amino-acid sequence is more expensive to synthesize, (2) all biological activity resides in the first 29 amino acids, and (3) it is equally susceptible to DPP-IV cleavage. Mod GRF 1-29 provides all the biological activity of full-length GHRH with improved stability, at lower synthesis cost.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

CJC-1295 Clinical Trials (ConjuChem Biotechnologies)

The most directly relevant clinical trial data for Mod GRF 1-29 comes from the development program for CJC-1295 with DAC, conducted by ConjuChem Biotechnologies (now Conjuchem LLC). While these trials used the DAC-conjugated version (longer-acting), they established the safety and efficacy of the tetrasubstituted GRF(1-29) backbone that Mod GRF 1-29 shares:

• Phase I single-dose study: Teichman et al. (2006) administered CJC-1295 with DAC to 34 healthy volunteers at doses of 30, 60, or 90 mcg/kg SC. Single doses produced sustained dose-dependent GH elevation (2–10 fold increases in mean GH concentration) lasting 6+ days. IGF-1 levels increased by 46–98% above baseline at the highest doses and remained elevated for 9–11 days. The compound was well-tolerated, with injection site reactions and transient flushing as the most common side effects (Teichman et al., 2006).
• Phase I multiple-dose study: Weekly SC dosing over 4 weeks produced sustained IGF-1 elevation with a dose-proportional response. No tachyphylaxis (desensitization) was observed with weekly dosing, suggesting that GHRH-R does not readily desensitize with intermittent pulsed activation (Teichman et al., 2006).
• Safety signal and program halt: The CJC-1295 clinical program was suspended in 2006 after one participant experienced a cardiac event (myocardial infarction). Subsequent investigation reportedly found the event was due to pre-existing cardiovascular disease rather than drug effect. However, ConjuChem did not resume the clinical program, and the compound was not further developed toward FDA approval.

GHRH/GHRP Synergy Studies

The pharmacological rationale for combining Mod GRF 1-29 with GHRPs is supported by decades of human studies demonstrating GHRH/GHRP synergy:

• Ghigo et al. (1997): This comprehensive review and meta-analysis of GHRH/GHRP combination studies established that co-administration of GHRH with any GHRP produces GH release that is 2–3 times greater than the sum of individual responses. This synergy was consistent across different GHRH and GHRP analogs, different age groups, and different body compositions (Ghigo et al., 1997).
• Bowers et al. (1990s–2000s): Cyril Bowers, one of the pioneers of GHRP development, published extensively on the synergy between GHRH and GHRP pathways, demonstrating that the dual-receptor activation model produces the most physiologically robust GH secretory response achievable through peptide stimulation (Bowers, 2001).
• Arvat et al. (multiple studies, 1995–2000): The University of Turin group published detailed dose-response and synergy data for GHRH combined with hexarelin, GHRP-2, and GHRP-6 in human subjects, demonstrating consistent synergistic amplification regardless of which specific GHRP was used (Arvat et al., 1995; Arvat et al., 1997).

Sermorelin Clinical Data (Applicable to GHRH Analog Class)

Sermorelin (native GRF 1-29) has the most extensive clinical history of any GHRH analog, including data that is broadly applicable to Mod GRF 1-29:

• GH deficiency diagnosis: Sermorelin was FDA-approved (as Geref) for diagnostic assessment of pituitary GH secretory capacity. The GH response to sermorelin reliably distinguishes GH-deficient from GH-sufficient adults (Jetton et al., 2005).
• GH augmentation in aging: Multiple studies demonstrated that sermorelin increases GH pulsatility and IGF-1 levels in elderly subjects, with improvements in body composition, bone density markers, and quality of life measures during treatment periods of 6–12 months (Vittone et al., 1997).
• Long-term safety: Sermorelin has been used clinically (primarily through compounding pharmacies) for decades without significant safety signals emerging. This long clinical track record provides reassurance about the general safety of GHRH receptor agonism as a therapeutic strategy.

DPP-IV Resistance and Modified GHRH Analog Development

• Ionescu and Bhatt (2006): This paper describes the rational design of modified GHRH analogs, including the tetrasubstituted GRF(1-29) that became Mod GRF 1-29. The four substitutions were selected through systematic structure-activity relationship studies to maximize DPP-IV resistance while preserving receptor binding and biological activity (Ionescu & Bhatt, 2006).
• Jetton et al. (2005): This study characterized DPP-IV cleavage kinetics for native GHRH and various modified analogs, providing the pharmacokinetic basis for the superiority of tetrasubstituted GRF over native sermorelin (Jetton et al., 2005).

GHRH Receptor Biology

• Mayo (1992): Foundational work on the molecular biology of the GHRH receptor, characterizing its G-protein coupling, cAMP/PKA signaling cascade, and role in somatotroph differentiation and GH gene expression. This work established the mechanistic framework for understanding how all GHRH analogs (including Mod GRF 1-29) produce their biological effects (Mayo, 1992).
• GHRH-R desensitization: In contrast to GHSR-1a (which desensitizes readily with potent agonists like hexarelin), the GHRH-R shows relatively stable expression and function with repeated agonist exposure, particularly when stimulation is pulsatile rather than continuous. This property supports the extended-use protocols common with Mod GRF 1-29 (Ghigo et al., 1997).

Limitations of the Evidence

• No dedicated Mod GRF 1-29 clinical trials: The specific tetrasubstituted GRF(1-29) peptide sold as “Mod GRF 1-29” or “CJC-1295 no DAC” has not been studied in formal, published, peer-reviewed clinical trials as a standalone compound. The evidence base relies on: (1) the CJC-1295 DAC trials (which share the same peptide backbone), (2) sermorelin clinical data (which shares the same receptor target), and (3) GHRH/GHRP synergy studies (which demonstrate the combination rationale).
• No Phase III data for any GHRH analog in GH optimization: Neither sermorelin, Mod GRF 1-29, nor CJC-1295 has completed Phase III trials for GH augmentation or anti-aging indications. The closest is sermorelin's diagnostic approval.
• Most combination protocol data is from clinical practice, not trials: The specific Mod GRF 1-29 + ipamorelin dosing protocols widely used in clinical practice are based on pharmacological principles, clinical experience, and extrapolation rather than randomized controlled trials of that specific combination.
• Long-term safety data is limited: Multi-year outcomes data for Mod GRF 1-29 use is not available in the published literature. Safety extrapolation relies on sermorelin’s clinical history and general GHRH pharmacology.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Mod GRF 1-29 has no FDA-approved indication. It has not been submitted for FDA review as a new drug. The clinical development of the related CJC-1295 with DAC by ConjuChem Biotechnologies was halted in 2006, and neither the DAC nor non-DAC version has been pursued through the U.S. regulatory pathway since.

The closely related peptide sermorelin (native GRF 1-29, the unmodified parent compound) was FDA-approved as Geref Diagnostic for assessment of pituitary GH secretory capacity. Geref was voluntarily withdrawn from the market by its manufacturer (EMD Serono) in 2008, not for safety reasons but due to commercial considerations. Sermorelin remains available through compounding pharmacies under the 503A and 503B compounding frameworks.

Compounding Pharmacy Access

Mod GRF 1-29 has been available through some compounding pharmacies, prescribed by licensed healthcare providers as a compounded preparation. However, the regulatory environment for compounded peptides is in significant flux as of 2026:

• FDA bulk drug substance evaluation: The FDA has been evaluating peptide ingredients under its bulk drug substance categorization process. Peptides that receive Category 2 designation may face restrictions on compounding. The specific status of Mod GRF 1-29 (tetrasubstituted GRF 1-29) in this process should be confirmed with the compounding pharmacy or regulatory counsel.
• 503A pharmacies: Patient-specific compounding by state-licensed pharmacies pursuant to individual prescriptions. These preparations must comply with state pharmacy board regulations and USP standards.
• 503B outsourcing facilities: FDA-registered outsourcing facilities that produce batch quantities under current good manufacturing practice (cGMP) conditions. These facilities are subject to FDA inspection and quality standards.
• Sermorelin as an alternative: Because sermorelin has a more established regulatory history (former FDA-approved product), it may be more readily available through compounding pharmacies. Some providers prescribe sermorelin when Mod GRF 1-29 availability is restricted.

Research Chemical Market

Mod GRF 1-29 is widely available through research chemical suppliers, typically sold as lyophilized powder in 2 mg or 5 mg vials labeled “for research purposes only.” Key considerations:

• Quality variability: Research chemical products are not manufactured under FDA drug cGMP standards. Third-party testing has found variable purity, with some products containing less peptide than labeled or containing degradation products.
• Naming confusion: Research chemical suppliers may label this peptide as “CJC-1295 no DAC,” “CJC-1295 without DAC,” “Mod GRF 1-29,” or “Modified GRF(1-29).” Buyers should verify they are getting the tetrasubstituted GRF(1-29) and not CJC-1295 with DAC, as these are fundamentally different compounds.
• Certificates of analysis: Reputable suppliers provide COAs from independent third-party laboratories showing HPLC purity (≥98%) and mass spectrometry confirmation of molecular identity.
• No regulatory oversight for human use: Products sold as research chemicals are not evaluated for human safety, potency, or sterility by any regulatory agency.

WADA Prohibited Status

WADA classifies Mod GRF 1-29 (and all GHRH analogs) as prohibited substances under Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Specifically, growth hormone releasing factors (including GHRH, its analogs, and fragments such as CJC-1295, sermorelin, and tesamorelin) are explicitly listed as prohibited at all times.

Athletes subject to WADA, USADA, or any national anti-doping authority testing must not use Mod GRF 1-29 under any circumstances.

International Regulatory Status

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Monthly Cost: Mod GRF 1-29 + Ipamorelin Protocol

Insurance Coverage

Mod GRF 1-29 is not covered by any insurance plan. Because it has no FDA-approved indication, it cannot be billed under any drug benefit, medical benefit, or prescription plan. All costs are out-of-pocket. Laboratory monitoring (GH, IGF-1, metabolic panel) may be covered under medical benefits depending on the provider's billing approach and the patient's insurance plan.

Additional Costs to Consider

• GHRP (ipamorelin): The cost estimates above include ipamorelin, which is typically priced similarly to Mod GRF 1-29. Some compounding pharmacies offer pre-mixed Mod GRF + ipamorelin vials at a combined price.
• Provider consultation: Initial consultations with peptide-knowledgeable providers: $100–$350. Follow-up visits: $50–$200.
• Laboratory monitoring: Baseline and follow-up labs (IGF-1, GH, fasting glucose, insulin, metabolic panel): $100–$400 per panel. Typically recommended at baseline, 4–6 weeks, and every 3–6 months during continued use.
• Supplies: Bacteriostatic water ($5–$15), insulin syringes ($10–$25 per 100), alcohol swabs ($5–$10). Minimal ongoing cost.

Cost Comparison: Mod GRF 1-29 + Ipamorelin vs. Other GH Therapies

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: Is “CJC-1295 without DAC” the same thing as Mod GRF 1-29?

Answer: In practice, yes. When people say “CJC-1295 without DAC” or “CJC-1295 no DAC,” they are referring to the tetrasubstituted GRF(1-29) peptide, which is the same compound as Mod GRF 1-29. The name “CJC-1295 without DAC” emerged because ConjuChem Biotechnologies developed both the DAC-conjugated version (true CJC-1295) and the non-conjugated precursor peptide. Strictly speaking, “CJC-1295” properly refers only to the DAC-conjugated version, and the non-DAC peptide should be called Mod GRF 1-29 or tetrasubstituted GRF(1-29). However, the naming convention “CJC-1295 no DAC” has become ubiquitous in the peptide community and is understood to mean Mod GRF 1-29. The critical thing is to ensure you are getting the correct product — the short-acting version (no DAC, ~30 min half-life) vs. the long-acting version (with DAC, ~6–8 day half-life), as these are fundamentally different compounds with different dosing, pharmacokinetics, and clinical profiles.

Q: Why not just use CJC-1295 with DAC? It’s more convenient (weekly dosing).

Answer: CJC-1295 with DAC offers dosing convenience (1–2x weekly vs. daily), but most peptide therapy clinicians prefer the non-DAC version for sustained use because it produces pulsatile GH release that mimics natural physiology. The body secretes GH in discrete pulses with trough periods between them. These troughs are important: they allow GH receptors to resensitize, prevent sustained insulin resistance, and maintain the metabolic flexibility that continuous GH elevation disrupts. CJC-1295 with DAC produces continuous, non-pulsatile GH elevation for nearly a week — a pharmacokinetic profile that more closely resembles exogenous GH injection than endogenous GH physiology. While this may be appropriate in some clinical contexts, for long-term GH optimization most clinicians consider pulsatile stimulation (Mod GRF + GHRP) to be safer and more physiologically appropriate (Teichman et al., 2006).

Q: Can I use Mod GRF 1-29 without a GHRP (by itself)?

Answer: You can, but the results will be significantly less impressive and more variable. Mod GRF 1-29 alone produces a moderate GH pulse, but its response is heavily dependent on the prevailing somatostatin tone. During periods of high somatostatin activity (which fluctuate unpredictably throughout the day), the GH response to Mod GRF alone may be blunted or minimal. Adding a GHRP like ipamorelin does two things: (1) it provides a synergistic second stimulus through a completely different receptor pathway (GHSR-1a), amplifying the GH pulse by 2–3x, and (2) it suppresses somatostatin release, reducing the variability of the response and ensuring a more reliable, robust GH pulse with each injection. For these reasons, Mod GRF 1-29 is considered a “support” peptide that works best in combination, not a standalone GH secretagogue (Ghigo et al., 1997).

Q: What is the “gold standard” peptide stack for GH?

Answer: The widely cited “gold standard” is Mod GRF 1-29 (100 mcg) + Ipamorelin (100 mcg), administered subcutaneously 2–3 times daily. This combination is preferred because it maximizes the GHRH/GHRP synergy while minimizing side effects. Ipamorelin is the most selective GHRP (no appetite stimulation, minimal cortisol/prolactin elevation, low desensitization), and Mod GRF 1-29 is the most stable short-acting GHRH analog. Together, they produce reliable, physiological GH pulses suitable for extended use. The “gold standard” designation reflects clinical consensus rather than formal clinical trial comparison, but it is the most commonly prescribed peptide combination in GH optimization practice.

Q: Does Mod GRF 1-29 cause desensitization like hexarelin?

Answer: Significantly less so. The GHRH receptor (activated by Mod GRF 1-29) does not desensitize as readily as the GHSR-1a receptor (activated by GHRPs like hexarelin). When paired with ipamorelin (the GHRP with the lowest desensitization profile), the Mod GRF + ipamorelin combination can generally be used for extended periods (3–6+ months) without significant loss of response. This is in sharp contrast to hexarelin, which shows ~50% loss of GH response by week 4 of continuous use. The key factors supporting sustained response are: (1) pulsatile stimulation (allowing receptor recovery between doses), (2) the inherent stability of GHRH-R expression under moderate agonist exposure, and (3) ipamorelin's mild receptor activation profile. That said, periodic breaks (e.g., 5 days on / 2 days off, or 3 months on / 1 month off) are still commonly recommended as a precautionary measure (Teichman et al., 2006).

Q: How is Mod GRF 1-29 different from sermorelin?

Answer: They target the same receptor and produce the same biological effect, but Mod GRF 1-29 is significantly more stable and potent per dose. Sermorelin is native GRF(1-29) without any modifications, which means it is rapidly cleaved by the enzyme DPP-IV within 5–7 minutes of injection. Mod GRF 1-29 has four amino acid substitutions that block DPP-IV cleavage and improve chemical stability, extending the half-life to ~30 minutes. In practical terms, this means: (1) Mod GRF 1-29 produces a larger, more consistent GH pulse per injection, (2) it requires lower doses (100 mcg vs. 200–500 mcg for sermorelin), and (3) it has better shelf stability. Sermorelin's advantage is its longer clinical track record and wider availability through compounding pharmacies (Jetton et al., 2005; Ionescu & Bhatt, 2006).

Q: Can I mix Mod GRF 1-29 and Ipamorelin in the same syringe?

Answer: Yes. This is standard practice. Both peptides are stable in aqueous solution at refrigerator temperatures, and they do not interact chemically in the syringe. Drawing both into a single insulin syringe reduces injection burden from two injections to one per dose. The common method is to draw the desired amount of ipamorelin first, then the desired amount of Mod GRF 1-29 into the same syringe, and inject subcutaneously. Some compounding pharmacies sell pre-mixed vials containing both peptides at a fixed ratio, further simplifying the process.

Q: Will Mod GRF 1-29 show up on a drug test?

Answer: On a standard employment or clinical drug test (which screens for drugs of abuse like cannabis, opioids, amphetamines, etc.), no. Mod GRF 1-29 would not be detected because standard panels do not screen for peptides. However, on an anti-doping test administered by WADA, USADA, or similar agencies, Mod GRF 1-29 can be detected using specialized LC-MS/MS methods designed for peptide hormones and their analogs. It is explicitly prohibited under WADA Section S2. Athletes subject to any anti-doping testing must not use this compound.

Q: Is it safe to use Mod GRF 1-29 long-term?

Answer: The available evidence supports a favorable safety profile for short-to-medium-term use (up to 6–12 months), extrapolated from sermorelin's clinical history, CJC-1295 trial data, and the general safety of GHRH receptor agonism. No serious adverse events have been attributed to GHRH analogs in published clinical studies. However, multi-year safety data specific to Mod GRF 1-29 does not exist. The theoretical long-term concerns (insulin resistance, IGF-1 and cancer risk, pituitary effects) are the same as for any GH-augmenting therapy. Regular laboratory monitoring (IGF-1, glucose, insulin, metabolic panel) and periodic clinical assessments are recommended for anyone using GH peptides on an ongoing basis. The pulsatile GH release pattern produced by Mod GRF + ipamorelin is considered inherently safer for long-term use than continuous GH elevation from CJC-1295 DAC or exogenous GH.

Q: Does food affect the response to Mod GRF 1-29?

Answer: Yes, significantly. Mod GRF 1-29 should be injected on an empty stomach, and eating should be avoided for at least 20–30 minutes post-injection. Elevated blood glucose (from carbohydrate intake) and elevated free fatty acids (from fat intake) both increase somatostatin release, which directly opposes the GH-releasing action of Mod GRF 1-29. Eating within the GH pulse window can reduce the GH response by 50% or more. This is the most commonly violated dosing rule and the most common reason for suboptimal results (Ghigo et al., 1997).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Sources & Further Reading

CJC-1295 / Mod GRF 1-29 Development and Clinical Data

• Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt DK. (2006) — "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism, 91(3):799-805. Phase I clinical trial demonstrating sustained GH and IGF-1 elevation from CJC-1295 with DAC; pharmacokinetic and safety data.
• Ionescu M, Bhatt DK. (2006) — "Development of a growth hormone releasing hormone analog with improved stability and bioavailability." Proceedings of the 88th Annual Meeting of the Endocrine Society. Development rationale and pharmacological characterization of tetrasubstituted GRF(1-29) and CJC-1295.

GHRH Receptor Pharmacology and Biology

• Mayo KE. (1992) — "Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone." Molecular Endocrinology, 6(10):1734-1744. Foundational characterization of the GHRH receptor and its signaling cascade.
• Jetton TL, Liang Y, Cincotta AH. (2005) — "DPP-IV inhibition, growth hormone-releasing factor, and glucose homeostasis." Journal of Endocrinology, 185(1):1-9. DPP-IV degradation kinetics for GHRH analogs and implications for modified peptide design.

GHRH/GHRP Synergy and GH Secretagogue Pharmacology

• Ghigo E, Arvat E, Muccioli G, Camanni F. (1997) — "Growth hormone-releasing peptides." European Journal of Endocrinology, 136(5):445-460. Comprehensive review of GHRH/GHRP synergy, dose-response data, and combination pharmacology in humans.
• Bowers CY. (2001) — "Unnatural growth hormone-releasing peptide begets natural ghrelin." Journal of Clinical Endocrinology and Metabolism, 86(4):1464-1469. Historical review of GHRP and GHRH development by a pioneer in the field.
• Arvat E, Ceda GP, Di Vito L, et al. (1995) — "Age-related variations in the neuroendocrine control of growth hormone secretion: effects of hexarelin." European Journal of Endocrinology, 132(2):152-158. GHRH/GHRP synergy data across age groups.
• Arvat E, Di Vito L, Broglio F, et al. (1997) — "Preliminary evidence that ghrelin and synthetic GH secretagogues show different desensitization patterns." Journal of Endocrinological Investigation, 20(10):611-615. Desensitization profiles for different GH secretagogues.

Sermorelin Clinical Data (GHRH Analog Class Evidence)

• Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997) — "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." Metabolism, 46(1):89-96. Sermorelin effects on GH pulsatility, IGF-1, and body composition in elderly subjects.
• Maccario M, Arvat E, Procopio M, et al. (1999) — "Metabolic modulation of the growth hormone-releasing activity of hexarelin in man." Metabolism, 48(9):1167-1174. Effects of metabolic status on GHRH/GHRP response.

Ghrelin Receptor (GHSR-1a) Discovery and Pharmacology

• Howard AD, Feighner SD, Cully DF, et al. (1996) — "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science, 273(5277):974-977. Identification of the GHS receptor (GHSR-1a) that GHRPs activate, complementing the GHRH-R that Mod GRF 1-29 activates.
• Kojima M, Hosoda H, Date Y, et al. (1999) — "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature, 402(6762):656-660. Discovery of ghrelin, the endogenous ligand for GHSR-1a and the basis for GHRH/GHRP synergy.

GH Physiology and Clinical Context

• Imbimbo BP, Mant T, Edwards M, et al. (1994) — "Growth hormone-releasing activity of hexarelin in humans." European Journal of Clinical Pharmacology, 46(5):421-425. Early human pharmacokinetic and GH response data for GHRP stimulation.
• Camanni F, Ghigo E, Arvat E. (2005) — "Growth hormone-releasing peptides and their analogs." Frontiers in Neuroendocrinology, 19(1):47-72. Comprehensive review of GHRP and GHRH analog development and clinical applications.
• Ghigo E, Arvat E, Gianotti L, et al. (1996) — "Short-term administration of hexarelin does not desensitize the GH response." Journal of Pediatric Endocrinology and Metabolism, 9(2):181-188. Short-term desensitization assessment relevant to cycling protocols.

Regulatory & Anti-Doping

• FDA: Bulk Drug Substances Used in Compounding — Category Lists
• WADA: Prohibited List (current year) — Section S2: Peptide Hormones, Growth Factors

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.